
Please try another search
By Investing.com Staff
Amgen (NASDAQ:AMGN) reported its Q2 results, with EPS of $4.65 coming in better than the consensus estimate of $4.39. Revenue grew 1% year-over-year to $6.59 billion, compared to the consensus estimate of $6.53 billion.
Total product sales grew 3% year-over-year. Unit volumes were up 10%, partially offset by a 6% lower net selling price and a 2% negative impact from foreign exchange.
"We are focused on delivering our long-term objectives by serving an ever-increasing number of patients around the world with our medicines," said Robert A. Bradway, chairman and chief executive officer. "We are advancing our pipeline and look forward to important readouts over the next few months."
The company provided its full 2022-year guidance, expecting EPS in the range of $17.00-$18.00, compared to the consensus of $17.40, and revenue in the range of $25.5-26.4 billion, compared to the consensus of $26.23 billion.
By Valerie Volcovici and Nichola Groom WASHINGTON (Reuters) - U.S. regulators raised doubts about Cheniere Energy (NYSE:LNG)'s decision to install higher-polluting gas-fired...
By Michael Elkins Morgan Stanley reiterated an outperform rating and $1150.00 price target on Tesla (NASDAQ:TSLA) following Morgan Stanley’s 4th Annual Intern Survey. The Survey of...
By Senad Karaahmetovic Shares of Poshmark (NASDAQ:POSH) are down almost 2% after the company offered a softer-than-expected quarterly revenue forecast. Poshmark reported a loss...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.